Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Ardelyx Inc(ARDX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARDX
09/28/2026: ARDX (3-star) is currently NOT-A-BUY. Pass it for now.
Ardelyx is a commercial-stage biotechnology company focused on developing therapies for cardiorenal and gastrointestinal diseases, most notably through its FDA-approved products IBSRELA and XPHOZAH. The company's main strength lies in its ability to bring first-in-class, non-systemic small molecule therapies to market, creating a differentiated niche in competitive therapeutic areas. Its primary growth story centers on the continued market adoption and expansion of these two products. However, investors must monitor significant risks, including intense competition from established pharmaceutical incumbents and the challenge of reaching consistent profitability. Ardelyx may best suit growth-oriented investors with a high risk tolerance for the volatile nature of the biotech sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active commercial expansion phase with significant potential for revenue scaling. |
| Momentum investor | Mixed fit | Momentum appeal depends on positive market adoption signals and successful execution of sales targets. |
| Value investor | Weak fit | The company is not yet consistently profitable, making traditional value metrics like P/E difficult to apply. |
| Dividend investor | Weak fit | The company is focused on growth and reinvestment, not income distribution. |
| Low-risk investor | Weak fit | Small-cap biotech stocks inherently carry high volatility and execution risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical, regulatory, and commercial updates. |
| Valuation risk | Medium / high | Investors often pay for future growth that is sensitive to commercial execution. |
| Competition risk (pharmaceutical incumbents) | High | Large incumbents have significant resources to defend their market share. |
| Business quality | Medium | The business is transitioning well but still lacks a long track record of sustained profitability. |
| Dividend income | Low / none | The company does not provide income, only capital appreciation potential. |
| Execution risk | High | Success relies heavily on the continued adoption of IBSRELA and XPHOZAH in competitive markets. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 128.3% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 883.00M USD | Price to earnings Ratio - | 1Y Target Price 12.9 |
Price to earnings Ratio - | 1Y Target Price 12.9 | ||
Volume (30-day avg) 4.0M shares | Beta 0.69 | 52 Weeks Range 3.33 - 8.40 | Updated Date 09/27/2026 |
52 Weeks Range 3.33 - 8.40 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Direct sales of IBSRELA and XPHOZAH to specialty pharmacies and distributors. | The company earns money by selling its two FDA-approved drugs directly to the healthcare market. |
| Collaboration and Licensing | Revenue from licensing agreements or partnerships for international markets. | Additional revenue may come from licensing its drug technology to partners in other regions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 9.93 | Enterprise Value 871.56M | Price to Sales(TTM) 1.96 |
Enterprise Value 871.56M | Price to Sales(TTM) 1.96 | ||
Enterprise Value to Revenue 1.93 | Enterprise Value to EBITDA 130.88 | Shares Outstanding 258.19M | Shares Floating 210.66M |
Shares Outstanding 258.19M | Shares Floating 210.66M | ||
Percent Insiders 3.17 | Percent Institutions 73.22 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Ardelyx Inc
Exchange NASDAQ | Headquarters Waltham, MA, United States | ||
IPO Launch date 2014-06-19 | President, CEO & Director Mr. Michael G. Raab | ||
Sector Healthcare | Industry Biotechnology | Full time employees 489 | Website https://www.ardelyx.com |
Full time employees 489 | Website https://www.ardelyx.com | ||
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.